Home > STEATOSI EPATICA e STEATOEPATITE NON ALCOLICA
STEATOSI EPATICA e STEATOEPATITE NON ALCOLICA
PUBBLICAZIONE CITOZEATEC: STEATOSI EPATICA
Liver steatosis development was obtained after high cholesterol diet (HCD) in C57BL6/N mice. Mice werepreliminarily treated for 10 days with multiple micronutrients contained in a commercial food supplement called Citozym (CIZ), and successively for 40 days with CIZ and HCD, to compare the protection effect of used compounds on liver metabolism and metabolic steatosis. At the end of the experiments, livers were dissected for histological examinations. Plasma total cholesterol (TCH), triacylglycerol (TAG) aspartate aminotransferase (AST), and alanine aminotransferase (ALT) concentrations were significantly higher in all HCD-fed mice. These data support a lipotoxic model of cholesterol-mediated hepatic steatosis. We found that the administration of CIZ to HCD-mouse model of steatosis significantly decreased plasma TCH,TAG, ALT and AST levels along with a reduction of the accumulated fat and inflammation in the liver. These findings suggest that a preventive and continuative treatment of CIZ exerts a protective effect against metabolic hepatosteatosis.